Our results are in agreement with those describing that melatonin decreases aromatase activity and expression in human breast cancer, glioma, and endothelial cells as well as in 3T3-L1 fibroblasts or breast cancer-associated fibroblasts [22,23,24,39,40]. This evidence concerns the gene CYP19A1 and central nervous system cancer.